Update on the pathophysiological activities of the cardiac molecule cardiotrophin-1 in obesity

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Asrih, Mohamed ^a   Mach, François ^a   Quercioli, Alessandra ^a   Dallegri, Franco ^b   Montecucco, Fabrizio ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTROPHIN 1; MITOGEN ACTIVATED PROTEIN KINASE; STAT1 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; CYTOKINE;

ADIPOSE TISSUE; HOMEOSTASIS; HUMAN; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECT; IMMUNOLOGY; LIPID METABOLISM; METABOLISM; PHYSIOLOGY; DRUG EFFECTS;

ADIPOSE TISSUE; ANIMALS; CYTOKINES; HUMANS; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; SIGNAL TRANSDUCTION;

EID: 84877279111     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/370715     Document Type: Review

References (60)

1. Jung R. T., Obesity as a disease. British Medical Bulletin 1997 53 2 307 321 2-s2.0-0030948614 (Pubitemid 27272042)
2. Ärnlöv J., Ingelsson E., Sundström J., Lind L., Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010 121 2 230 236 2-s2.0-74949084667 10.1161/CIRCULATIONAHA.109.887521
3. Must A., Spadano J., Coakley E. H., Field A. E., Colditz G., Dietz W. H., The disease burden associated with overweight and obesity. Journal of the American Medical Association 1999 282 16 1523 1529 2-s2.0-0032742418 10.1001/jama.282.16.1523 (Pubitemid 29504045)
4. Miller Y. I., Choi S.-H., Wiesner P., Fang L., Harkewicz R., Hartvigsen K., Boullier A., Gonen A., Diehl C. J., Que X., Montano E., Shaw P. X., Tsimikas S., Binder C. J., Witztum J. L., Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circulation Research 2011 108 2 235 248 10.1161/CIRCRESAHA.110.223875
5. Ouchi N., Parker J. L., Lugus J. J., Walsh K., Adipokines in inflammation and metabolic disease. Nature Reviews Immunology 2011 11 2 85 97 2-s2.0-79151484704 10.1038/nri2921
6. Ku I. A., Farzaneh-Far R., Vittinghoff E., Zhang M. H., Na B., Whooley M. A., Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease: the Heart and Soul Study. Atherosclerosis 2011 217 2 503 508 2-s2.0-79960700893 10.1016/j.atherosclerosis. 2010.10.047
7. McMahon M., Skaggs B. J., Sahakian L., Grossman J., FitzGerald J., Ragavendra N., Charles-Schoeman C., Chernishof M., Gorn A., Witztum J. L., Wong W. K., Weisman M., Wallace D. J., La Cava A., Hahn B. H., High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Annals of the Rheumatic Diseases 2011 70 9 1619 1624 2-s2.0-80051471532 10.1136/ard.2010.142737
8. Febbraio M. A., Gp130 receptor ligands as potential therapeutic targets for obesity. Journal of Clinical Investigation 2007 117 4 841 849 2-s2.0-34147159710 10.1172/JCI30453 (Pubitemid 46556736)
9. Tilg H., Moschen A. R., Inflammatory mechanisms in the regulation of insulin resistance. Molecular Medicine 2008 14 3-4 222 231 2-s2.0-41649093318 10.2119/2007-00119.Tilg (Pubitemid 351481853)
10. Pennica D., King K. L., Shaw K. J., Luis E., Rullamas J., Luoh S. M., Darbonne W. C., Knutzon D. S., Yen R., Chien K. R., Baker J. B., Wood W. I., Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proceedings of the National Academy of Sciences of the United States of America 1995 92 4 1142 1146 2-s2.0-0028816906 10.1073/pnas.92.4.1142
11. Latchman D. S., Cardiotrophin-1 (CT-1): a novel hypertrophic and cardioprotective agent. International Journal of Experimental Pathology 1999 80 4 189 196 2-s2.0-0032852488 10.1046/j.1365-2613.1999.00114.x (Pubitemid 29469031)
12. Jin H., Yang R., Keller G. A., Ryan A., Ko A., Finkle D., Swanson T. A., Li W., Pennica D., Wood W. I., Paoni N. F., In vivo effects of cardiotrophin-1. Cytokine 1996 8 12 920 926 2-s2.0-0030512316 10.1006/cyto.1996.0123 (Pubitemid 27091193)
13. Natal C., Fortuño M. A., Restituto P., Bazán A., Colina I., Díez J., Varo N., Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. American Journal of Physiology- Endocrinology and Metabolism 2008 294 1 E52 E60 2-s2.0-38349016317 10.1152/ajpendo.00506.2007
14. Zvonic S., Hogan J. C., Arbour-Reily P., Mynatt R. L., Stephens J. M., Effects of cardiotrophin on adipocytes. Journal of Biological Chemistry 2004 279 46 47572 47579 2-s2.0-9144232427 10.1074/jbc.M403998200 (Pubitemid 39540902)
15. Marquès J. M., Belza I., Holtmann B., Pennica D., Prieto J., Bustos M., Cardiotrophin-1 is an essential factor in the natural defense of the liver against apoptosis. Hepatology 2007 45 3 639 648 2-s2.0-33947362493 10.1002/hep.21508 (Pubitemid 46450615)
16. Iñiguez M., Berasain C., Martinez-Ansó E., Bustos M., Fortes P., Pennica D., Avila M. A., Prieto J., Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. Journal of Experimental Medicine 2006 203 13 2809 2815 2-s2.0-33845878554 10.1084/jem.20061421 (Pubitemid 46026159)
17. Quiros Y., Sánchez-González P. D., López- Hernández F. J., Morales A. I., López-Novoa J. M., Cardiotrophin-1 administration prevents the renal toxicity of iodinated contrast media in rats. Toxicological Sciences 2013 132 493 501
18. Moreno-Aliaga M. J., Pérez-Echarri N., Marcos-Gómez B., Larequi E., Viollet B., Gimenez I., Martínez J. A., Prieto J., Bustos M., Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metabolism 2011 14 2 242 253 10.1016/j.cmet.2011.05.013
19. Pennica D., Swanson T. A., Shaw K. J., Kuang W. J., Gray C. L., Beatty B. G., Wood W. I., Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization. Cytokine 1996 8 3 183 189 2-s2.0-0029937696 10.1006/cyto.1996.0026 (Pubitemid 26111115)
20. Sheng Z., Pennica D., Wood W. I., Chien K. R., Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 1996 122 2 419 428 2-s2.0-0030039948 (Pubitemid 26056393)
21. Yoshida K., Taga T., Saito M., Suematsu S., Kumanogoh A., Tanaka T., Fujiwara H., Hirata M., Yamagami T., Nakahata T., Hirabayashi T., Yoneda Y., Tanaka K., Wang W. Z., Mori C., Shiota K., Yoshida N., Kishimoto T., Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proceedings of the National Academy of Sciences of the United States of America 1996 93 1 407 411 2-s2.0-9044222888 10.1073/pnas.93.1.407 (Pubitemid 26041485)
22. Betz U. A. K., Bloch W., van den Broek M., Yoshida K., Taga T., Kishimoto T., Addicks K., Rajewsky K., Müller W., Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. Journal of Experimental Medicine 1998 188 10 1955 1965 2-s2.0-0032539008 10.1084/jem.188.10.1955 (Pubitemid 28536782)
23. Hirota H., Chen J., Betz U. A. K., Rajewsky K., Gu Y., Ross J., Müller W., Chien K. R., Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999 97 2 189 198 2-s2.0-0033574574 (Pubitemid 29194270)
24. Asai S., Saito Y., Kuwahara K., Mizuno Y., Yoshimura M., Higashikubo C., Tsuji T., Kishimoto I., Harada M., Hamanaka I., Takahashi N., Yasue H., Nakao K., The heart is a source of circulating cardiotrophin-1 in humans. Biochemical and Biophysical Research Communications 2000 279 2 320 323 2-s2.0-0034694801 10.1006/bbrc.2000.3932 (Pubitemid 32016715)
25. Zolk O., Ng L. L., O'Brien R. J., Weyand M., Eschenhagen T., Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 2002 106 12 1442 1446 2-s2.0-0037126009 10.1161/01.CIR.0000033117.39335.DF
26. López-Andrés N., Calvier L., Labat C., Fay R., Díez J., Benetos A., Zannad F., Lacolley P., Rossignol P., Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension 2013 61 1 120 129 10.1161/HYPERTENSIONAHA.112. 201699
27. Ishikawa M., Saito Y., Miyamoto Y., Kuwahara K., Ogawa E., Nakagawa O., Harada M., Masuda I., Nakao K., cDNA cloning of rat cardiotrophin-1 (CT-1): augmented expression of CT-1 gene in ventricle of genetically hypertensive rats. Biochemical and Biophysical Research Communications 1996 219 2 377 381 2-s2.0-0029996496 10.1006/bbrc.1996.0241 (Pubitemid 26090907)
28. Takimoto Y., Aoyama T., Pennica D., Inoue R., Shinoda E., Hattori R., Yui Y., Sasayama S., Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat. Journal of Molecular and Cellular Cardiology 2000 32 10 1821 1830 2-s2.0-0033744492 10.1006/jmcc.2000.1218
29. Robador P. A., San Jos G., Rodrguez C., Guadall A., Moreno M. U., Beaumont J., Fortuo A., Dez J., Martnez-Gonzlez J., Zalba G., HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. Cardiovascular Research 2011 92 2 247 255 10.1093/cvr/cvr202
30. Fukuzawa J., Booz G. W., Hunt R. A., Shimizu N., Karoor V., Baker K. M., Dostal D. E., Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. Hypertension 2000 35 6 1191 1196 2-s2.0-0034086490 (Pubitemid 30413649)
31. Voges D., Zwickl P., Baumeister W., The 26S proteasome: a molecular machine designed for controlled proteolysis. Annual Review of Biochemistry 1999 68 1015 1068 2-s2.0-0032867676 10.1146/annurev.biochem.68.1.1015 (Pubitemid 29449214)
32. Hayashi T., Faustman D., NOD mice are defective in proteasome production and activation of NF- B. Molecular and Cellular Biology 1999 19 12 8646 8659 2-s2.0-0033499621 (Pubitemid 30414057)
33. Hishinuma S., Funamoto M., Fujio Y., Kunisada K., Yamauchi-Takihara K., Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochemical and Biophysical Research Communications 1999 264 2 436 440 2-s2.0-0033595748 10.1006/bbrc.1999.1535 (Pubitemid 29516105)
34. Ateghang B., Wartenberg M., Gassmann M., Sauer H., Regulation of cardiotrophin-1 expression in mouse embryonic stem cells by HIF-1 α and intracellular reactive oxygen species. Journal of Cell Science 2006 119 6 1043 1052 2-s2.0-33645748498 10.1242/jcs.02798
35. López-Andrés N., Iñigo C., Gallego I., Díez J., Fortuño M. A., Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinology 2008 149 10 4970 4978 2-s2.0-53249125773 10.1210/en.2008-0120
36. Jiang Z. S., Jeyaraman M., Wen G. B., Fandrich R. R., Dixon I. M. C., Cattini P. A., Kardami E., High- but not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1. Journal of Molecular and Cellular Cardiology 2007 42 1 222 233 2-s2.0-33845647351 10.1016/j.yjmcc.2006.09.002 (Pubitemid 44958615)
37. Janjua S., Lawrence K. M., Ng L. L., Latchman D. S., The cardioprotective agent urocortin induces expression of CT-1. Cardiovascular Toxicology 2003 3 3 255 261 2-s2.0-0142117326 10.1385/CT:3:3:255 (Pubitemid 37296077)
38. Marney A. M., Brown N. J., Aldosterone and end-organ damage. Clinical Science 2007 113 5-6 267 278 2-s2.0-34548500119 10.1042/CS20070123 (Pubitemid 47372685)
39. Otkjaer K., Holtmann H., Kragstrup T. W., Paludan S. R., Johansen C., Gaestel M., Kragballe K., Iversen L., The p38 MAPK regulates IL-24 expression by stabilization of the 3′ UTR of IL-24 mRNA. PLoS One 2010 5 1 e8671 10.1371/journal.pone.0008671
40. Ilercil A., Devereux R. B., Roman M. J., Paranicas M., O'Grady M. J., Welty T. K., Robbins D. C., Fabsitz R. R., Howard B. V., Lee E. T., Relationship of impaired glucose tolerance to left ventricular structure and function: the strong heart study. American Heart Journal 2001 141 6 992 998 2-s2.0-0345698688 10.1067/mhj.2001.115302 (Pubitemid 32477012)
41. Galvan A. Q., Galetta F., Natali A., Muscelli E., Sironi A. M., Cini G., Camastra S., Ferrannini E., Insulin resistance and hyperinsulinemia: no independent relation to left ventricular mass in humans. Circulation 2000 102 18 2233 2238 2-s2.0-0034739483
42. Liu J., Liu Z., Huang F., Xing Z., Wang H., Li Z., Pioglitazone inhibits hypertrophy induced by high glucose and insulin in cultured neonatal rat cardiomyocytes. Pharmazie 2007 62 12 925 929 2-s2.0-37349101590 10.1691/ph.2007.12.7553 (Pubitemid 350305769)
43. Calabrò P., Limongelli G., Riegler L., Maddaloni V., Palmieri R., Golia E., Roselli T., Masarone D., Pacileo G., Golino P., Calabrò R., Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. Journal of Molecular and Cellular Cardiology 2009 46 2 142 148 10.1016/j.yjmcc.2008.11.002
44. Wollert K. C., Taga T., Saito M., Narazaki M., Kishimoto T., Glembotski C. C., Vernallis A. B., Heath J. K., Pennica D., Wood W. I., Chien K. R., Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy: assembly of sarcomeric units in series via gp130/leukemia inhibitory factor receptor-dependent pathways. Journal of Biological Chemistry 1996 271 16 9535 9545 2-s2.0-0029933362
45. Craig R., Wagner M., McCardle T., Craig A. G., Glembotski C. C., The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF- B. Journal of Biological Chemistry 2001 276 40 37621 37629 2-s2.0-0035813098 10.1074/jbc.M103276200
46. Takahashi N., Saito Y., Kuwahara K., Harada M., Tanimoto K., Nakagawa Y., Kawakami R., Nakanishi M., Yasuno S., Usami S., Yoshimura A., Nakao K., Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. Journal of Molecular and Cellular Cardiology 2005 38 1 185 192 2-s2.0-19944380417 10.1016/j.yjmcc.2004.10.016 (Pubitemid 40038665)
47. Heinrich P. C., Behrmann I., Muller-Newen G., Schaper F., Graeve L., Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochemical Journal 1998 334, part 2 297 314 2-s2.0-0032168152 (Pubitemid 28448572)
48. Tian Z. J., Cui W., Li Y. J., Hao Y. M., Du J., Liu F., Zhang H., Zu X. G., Liu S. Y., Chen L., An W., Different contributions of STAT3, ERK1/2, and PI3-K signaling to cardiomyocyte hypertrophy by cardiotrophin-1. Acta Pharmacologica Sinica 2004 25 9 1157 1164 2-s2.0-4544376542 (Pubitemid 39237407)
49. Sartipy P., Loskutoff D. J., Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2003 100 12 7265 7270 2-s2.0-0038809142 10.1073/pnas.1133870100 (Pubitemid 36706427)
50. Wellen K. E., Hotamisligil G. S., Inflammation, stress, and diabetes. Journal of Clinical Investigation 2005 115 5 1111 1119 2-s2.0-18244370762 10.1172/JCI200525102 (Pubitemid 40629025)
51. Odegaard J. I., Chawla A., Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013 339 6116 172 177 10.1126/science.1230721
52. Hotamisligil G. S., Shargill N. S., Spiegelman B. M., Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Science 1993 259 5091 87 91 2-s2.0-0027459878 (Pubitemid 23036092)
53. Shoelson S. E., Lee J., Goldfine A. B., Inflammation and insulin resistance. Journal of Clinical Investigation 2006 116 7 1793 1801 2-s2.0-33745861300 10.1172/JCI29069
54. Donath M. Y., Shoelson S. E., Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology 2011 11 2 98 107 2-s2.0-79151478555 10.1038/nri2925
55. López-Andrés N., Rousseau A., Akhtar R., Calvier L., Iñigo C., Labat C., Zhao X., Cruickshank K., Díez J., Zannad F., Lacolley P., Rossignol P., Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension 2012 60 2 563 573 10.1161/HYPERTENSIONAHA.112.194407
56. Limongelli G., Calabrò P., Maddaloni V., Russo A., Masarone D., D'Aponte A., Roselli T., Bonauro R., D'Alessandro R., D'Andrea A., Pacileo G., Limongelli F. M., Calabro' R., Cardiotrophin-1 and TNF- α circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. Cytokine 2010 50 3 245 247 2-s2.0-77952544188 10.1016/j.cyto.2009. 12.007
57. Jean-Louis G., Zizi F., Clark L. T., Brown C. D., McFarlane S. I., Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. Journal of Clinical Sleep Medicine 2008 4 3 261 272 2-s2.0-47849094262 (Pubitemid 352039439)
58. Jung C., Fritzenwanger M., Figulla H. R., Cardiotrophin-1 in adolescents: impact of obesity and blood pressure. Hypertension 2008 52, article e6 2-s2.0-49849097294
59. Asrih M., Gardier S., Papageorgiou I., Montessuit C., Dual effect of the heart-targeting cytokine cardiotrophin-1 on glucose transport in cardiomyocytes. Journal of Molecular and Cellular Cardiology 2013 56 1 106 115 10.1016/j.yjmcc.2012.12.015
60. Zolk O., Engmann S., Münzel F., Krajcik R., Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. American Journal of Physiology-Endocrinology and Metabolism 2005 288 6 E1214 E1221 2-s2.0-19444370317 10.1152/ajpendo.00261.2004 (Pubitemid 40726809)